DORIDEN
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
Apr 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DORIDEN is an oral small-molecule capsule approved in 1957 as a legacy NDA product by Sanofi. The specific indication and mechanism of action are not currently documented in available data. This product represents a historical pharmaceutical asset with declining market relevance.
LOE Approaching
With LOE approaching and no current spending data, this asset is in managed decline with minimal commercial team expansion expected.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DORIDEN offers minimal career growth opportunity with zero linked job postings and approaching loss of exclusivity. Roles available are typically in legacy product management, focused on managed decline and transition planning rather than expansion.
Brand Manager (Legacy)Market Access Specialist
Worked on DORIDEN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.